According to the research of GOSREPORTS “Global COPD and Asthma Devices Market – Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 – 2020″”, the global COPD and asthma devices market would reach $34.3 billionby 2020, registering a CAGR of 4.5% during 2014 – 2020. Considering the growth and market size, Dry Powder Inhalers (DPIs) will be the most lucrative market segment of the COPD and Asthma devices (inhalers) market by 2020. Metered Dose Inhalers (MDIs) are the largest revenue generating segment currently and would maintain the stand till 2020.The need for urgency in medication and portability of the drug delivery devices will drive the growth for COPD and Asthma devices. Despite notable advantages of the COPD and Asthma devices, some factors such as environmental concerns are likely to impede the growth of COPD and Asthma devices market. It is observed that the inhalers, particularly the MDIs, release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA), which is negatively impacting growth of the MDIs segment. Consumption pattern will shift to better alternatives, namely the DPIs. The Soft Mist Inhalers (SMIs), which are another type of inhalers, deliver metered dosage of medication as a soft mist. Such form of drug delivery is ~65% to 80% more efficacious than its peers and will eventually display higher growth as compared to its peers.

Detailed report：
http://www.gosreports.com/?s=COPD+and+asthma+devices+market

http://www.gosreports.com/global-copd-and-asthma-devices-market-product/

“CHAPTER 1 INTRODUCTION

1.1 Report Description

1.2 Reason for doing the study

1.3 Key Benefits

1.4 Key Market Segments

1.5 Key Audiences

1.6 Research Methodology

1.6.1 Secondary Research

1.6.2 Primary Research

1.6.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective

2.2 Market beyond what to expect by 2025 ($Million)

2.2.1 Moderate growth scenario

2.2.2 Rapid growth scenario

2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope

3.2 Key Findings

3.2.1 Top Factors Impacting on global COPD and Asthma devices market

3.2.2 Top Investment Pockets of global COPD and Asthma devices market

3.2.3 Top winning strategies of global COPD and Asthma devices market

3.3 Government Regulations

3.4 Porter’s Five force Analysis

3.5 Value chain analysis

3.6 Clinical Trials

3.7 Patent Analysis

3.8 Market Share Analysis, 2013

3.9 Market Dynamics

3.9.1 Drivers

3.9.2 Restraints

3.9.3 Opportunities

CHAPTER 4 GLOBAL COPD AND ASTHMA DEVICES MARKET BY PRODUCT TYPE, 2013-2020, $MILLION

4.1 Inhalers

4.1.1 Drug powder inhalers (DPIs)

4.1.1.1 Key market trends

4.1.1.2 Key growth factors and opportunities

4.1.1.3 Market size and forecast

4.1.2 Metered Dose Inhalers (MDIs)

4.1.2.1 Key market trends

4.1.2.2 Key growth factors and opportunities

4.1.2.3 Market size and forecast

4.1.3 Soft Mist Inhalers (SMIs)

4.1.3.1 Key market trends

4.1.3.2 Key growth factors and opportunities

4.1.3.3 Market size and forecast

4.2 Nebulizers

4.2.1 Compressor Nebulizers

4.2.2 Ultrasonic Nebulizers

4.2.3 Mesh Nebulizers

CHAPTER 5 GLOBAL COPD AND ASTHMA DEVICES MARKET BY GEOGRAPHY, 2013-2020, $MILLION

5.1 North America

5.1.1 Key market trends

5.1.2 Key growth factors and opportunities

5.1.3 Market size and forecast

5.1.4 United States

5.1.4.1 Market size and forecast

5.1.5 Canada

5.1.5.1 Market size and forecast

5.1.6 Mexico

5.1.6.1 Market size and forecast

5.1.7 Others

5.1.7.1 Market size and forecast

5.2 Europe

5.2.1 Key market trends

5.2.2 Key growth factors and opportunities

5.2.3 Market size and forecast

5.2.4 France

5.2.4.1 Market size and forecast

5.2.5 Germany

5.2.5.1 Market size and forecast

5.2.6 United Kingdom

5.2.6.1 Market size and forecast

5.2.7 Others

5.2.7.1 Market size and forecast

5.3 Asia-Pacific

5.3.1 Key market trends

5.3.2 Key growth factors and opportunities

5.3.3 Market size and forecast

5.3.4 India

5.3.4.1 Market size and forecast

5.3.5 China

5.3.5.1 Market size and forecast

5.3.6 Japan

5.3.6.1 Market size and forecast

5.3.7 Australia

5.3.7.1 Market size and forecast

5.3.8 Others

5.3.8.1 Market size and forecast

5.4 LAMEA

5.4.1 Key market trends

5.4.2 Key growth factors and opportunities

5.4.3 Market size and forecast

5.4.4 Latin America

5.4.4.1 Market size and forecast

5.4.5 Middle East

6.4.5.1 Market size and forecast

5.4.6 Africa

5.4.6.1 Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1 GlaxoSmithKline Plc

6.1.1 Overview

6.1.2 Company snapshot

6.1.3 Financial performance

6.1.4 Operating segment

6.1.5 Strategic moves and developments

6.1.6 SWOT analysis

6.2 Novartis AG

6.2.1 Overview

6.2.2 Company snapshot

6.2.3 Financial performance

6.2.4 Operating segment

6.2.5 Strategic moves and developments

6.2.6 SWOT analysis

6.3 Merck & Co., Inc.

6.3.1 Overview

6.3.2 Company snapshot

6.3.3 Financial performance

6.3.4 Operating segment

6.3.5 Strategic moves and developments

6.3.6 SWOT analysis

6.4 Philips Healthcare

6.4.1 Overview

6.4.2 Company snapshot

6.4.3 Financial performance

6.4.4 Operating segment

6.4.5 Strategic moves and developments

6.4.6 SWOT analysis

6.5 AstraZeneca Plc

6.5.1 Overview

6.5.2 Company snapshot

6.5.3 Financial performance

6.5.4 Operating segment

6.5.5 Strategic moves and developments

6.5.6 SWOT analysis

6.6 3M Health Care

6.6.1 Overview

6.6.2 Company snapshot

6.6.3 Financial performance

6.6.4 Operating segment

6.6.5 Strategic moves and developments

6.6.6 SWOT analysis

6.7 Allied Healthcare Products Inc.

6.7.1 Overview

6.7.2 Company snapshot

6.7.3 Financial performance

6.7.4 Operating segment

6.7.5 Strategic moves and developments

6.7.6 SWOT analysis

6.8 GF Health Products Inc.

6.8.1 Overview

6.8.2 Company snapshot

6.8.3 Financial performance

6.8.4 Operating segment

6.8.5 Strategic moves and developments

6.8.6 SWOT analysis

6.9 Sunovion Pharmaceuticals Inc.

6.9.1 Overview

6.9.2 Company snapshot

6.9.3 Financial performance

6.9.4 Operating segment

6.9.5 Strategic moves and developments

6.9.6 SWOT analysis

6.10 Smith Medicals

6.10.1 Overview

6.10.2 Company snapshot

6.10.3 Financial performance

6.10.4 Operating segment

6.10.5 Strategic moves and developments

6.10.6 SWOT analysis

6.11 Lincare Holdings Inc.

6.11.1 Overview

6.11.2 Company snapshot

6.11.3 Financial performance

6.11.4 Operating segment

6.11.5 Strategic moves and developments

6.11.6 SWOT analysis

6.12 Baxter International

6.12.1 Overview

6.12.2 Company snapshot

6.12.3 Financial performance

6.12.4 Operating segment

6.12.5 Strategic moves and developments

6.12.6 SWOT analysis

Nebulizers, electric or battery powered machines that dispense medication as a fine mist, are ideal for home healthcare set-up for debilitated patients, geriatrics and children. Nebulizers segment thus holds about 13% of the global COPD and Asthma devices market; however, the nebulizers market is forecast to have diminishing growth through 2020 as nebulizers are rendered ineffectual, as POC or portable COPD and Asthma devices due to its larger set up.

Key findings of the study:

Drug powder inhalers (DPIs) segment will grow at a CAGR of 5.3% during the forecast period, fastest among all
North American market would be one of the most lucrative markets, in terms of growth
European market for COPD and asthma devices would reach $10 billion by 2020, with the CAGR of 4.8%
Within the nebulizers segment markets, compressor nebulizers would be most lucrative, growing at 7% CAGR during the forecast period and compressor nebulizers would garner 81.5% market share by 2020
Specific focus to achieve product differentiation and thus gain competitive advantage drives the development of new product variants of COPD and Asthma devices. In accordance to the afore-mentioned trend, the market has witnessed steady stream of product launch. Key product manufacturing companies profiled in the report include GlaxoSmithKline Plc, Novartis AG, Merck & Co., Inc., AstraZeneca Plc, Philips Healthcare, 3M Health Care, Allied Healthcare Products Inc., Sunovion Pharmaceuticals Inc., GF Healthcare Products, Smith Medicals, Lincare Holdings Inc. and Baxter International.”

Contacts Us

Joanna | Executive - International Business and partner Relations

E-mail: [email protected] | Tel: 001-510-400-8520

Web: www.gosreports.com